南京醫藥(600713.SH):南京鶴齡擬投建中藥煎制服務中心遷址過渡項目
格隆匯3月30日丨南京醫藥(600713.SH)公佈,公司控股子公司南京藥業股份有限公司(“南京藥業”)之全資子公司南京鶴齡藥事服務有限公司(“南京鶴齡”)擬投資建設中藥煎制服務中心遷址過渡項目,投資總額不超過4100萬元人民幣。
其中,南京鶴齡擬以代建合作方式租賃南京中山製藥有限公司(“中山製藥”)按照中藥煎制中心生產、存儲要求擬新建的廠房,租賃建築物面積約7000平方米,租賃期限不超過10年,租金總額合計不超過3193.42萬元(其中包含以租金形式支付的廠房裝修改造費用1423萬元)。南京鶴齡為搬遷改造購置中藥煎制服務中心生產設備等費用合計不超過906.58萬元。
鑑於窯崗村33-35號已被列入南京市雨花台區老城區改造拆遷範圍,且為進一步提升煎制中心生產管理整體水平,滿足“智能化中藥製劑湯煮基地”的中藥藥事服務戰略發展要求,南京鶴齡擬代建合作方式,投資建設南京鶴齡藥事服務有限公司中藥煎制服務中心遷址過渡項目。
該項目是公司中藥藥事服務項目的核心主體和中藥專業線創新推廣的有效載體,也是公司與省三甲重點醫院戰略合作項目的重要組成部分,對公司主營業務發展起到積極促進作用。
按照項目實施進度計劃,南京鶴齡中藥煎制中心擬於2020年年底完成整體搬遷,2021年1月份正式投入運營。受目前新冠肺炎疫情影響,相關流程推進時間可能有所調整。公司將保持與中山製藥密切溝通配合,加快項目規劃、環評、施工等相關工作進度,協調各方資源,盡最大可能按照既定計劃推進項目實施,滿足南京鶴齡中藥煎制中心業務發展需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.